Authors:
Decensi, A
Torrisi, R
Bruno, S
Costantini, M
Curotto, A
Nicolo, G
Malcangi, B
Baglietto, L
Bruttini, GP
Gatteschi, B
Rondanina, G
Varaldo, M
Perloff, M
Malone, WF
Bruzzi, P
Citation: A. Decensi et al., Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point, CANC EPID B, 9(10), 2000, pp. 1071-1078
Authors:
Bruno, S
Torrisi, R
Costantini, M
Baglietto, L
Fontana, V
Gatteschi, B
Melioli, G
Nicolo, G
Curotto, A
Malcangi, B
Bruttini, GP
Varaldo, M
Bruzzi, P
Decensi, A
Citation: S. Bruno et al., Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial, J CELL BIOC, 76(2), 2000, pp. 311-321
Authors:
Barbui, P
Casadei, G
Ceccopieri, C
Ciotola, R
Comeri, G
Cruciani, E
de Joanna, F
Ferrando, U
Gritti, A
Guarna, A
Jacobellis, U
Lai, S
Leoni, S
Maccanico, A
Miano, L
Milani, C
Borin, R
Nicolosi, D
Pacifico, P
Parma, A
Rossetti, R
Sacca, V
Trocino, S
Valentino, RV
Varaldo, M
Citation: P. Barbui et al., Safety, efficacy and impact on patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH, EUR UROL, 37(6), 2000, pp. 680-686
Authors:
Semino, C
Pietra, G
Semino, A
Falco, M
Varaldo, M
Melioli, G
Citation: C. Semino et al., Normal epithelial cells modulating HLA class I surface molecules are susceptible to lysis mediated by CD3(+) and CD3(-) "nonspecific" killer cells, CELL IMMUN, 190(2), 1998, pp. 183-190